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Abstract Cardiovascular disease is the major cause of mor-
tality in type 2diabetes mellitus. The criteria for the selection
of those asymptomatic patients with type 2 diabetes who
should undergo cardiac screening and the therapeutic con-
sequences of screening remain controversial. Non-invasive
techniques as markers of atherosclerosis and myocardial
ischaemia may aid risk stratification and the implementation
of tailored therapy for the patient with type 2 diabetes. In the
presentarticlewereviewtheliterature ontheimplementation
of non-invasive vascular tools and cardiac imaging tech-
niques in this patient group. The value of these techniques as
endpoints in clinical trials and as risk estimators in asymp-
tomatic diabetic patients is discussed. Carotid intima–media
thickness, arterial stiffness and flow-mediated dilation are
abnormal long before the onset of type 2 diabetes. These
vascular tools are therefore most likely to be useful for the
identification of ‘at risk’ patients during the early stages of
atherosclerotic disease. The additional value of these tools in
risk stratification and tailored therapy in type 2 diabetes
remains to be proven. Cardiac imaging techniques are more
justified in individuals with a strong clinical suspicion of
advanced coronary heart disease (CHD). Asymptomatic
myocardial ischaemia can be detected by stress echocardiog-
raphy and myocardial perfusion imaging. The more recently
developed non-invasive multi-slice computed tomography
angiography is recommended for exclusion of CHD, and
can therefore be used to screen asymptomatic patients with
type 2 diabetes, but has the associated disadvantages of
high radiation exposure and costs. Therefore, we propose
an algorithm for the screening of asymptomatic diabetic
patients, the first step of which consists of coronary artery
calcium score assessment and exercise ECG.
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Abbreviations
AIx augmentation index
CAC coronary artery calcium
CIMT carotid intima–media thickness
CVD cardiovascular disease
DIAD Detection of Ischemia in Asymptomatic
Diabetics
FMD flow-mediated dilation
IMT intima–media thickness
MPI myocardial perfusion imaging
MSCT multi-slice computed tomography
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Introduction
Cardiovascular disease (CVD) is the leading cause of
mortality in type 2 diabetes mellitus [1]. Current guidelines
on the treatment of dyslipidaemia and hypertension in
diabetesrecommendrigorous primaryprevention, with target
lipid and blood pressure levels similar to those used for
secondary prevention in non-diabetic patients [2]. To date,
there is much debate as to whether all diabetic patients will
benefit from this strategy and whether risk stratification
should be attempted.
Non-invasive imaging techniques as markers of athero-
sclerosis and myocardial ischaemia may help risk stratifi-
cation and the implementation of tailored therapy for the
individual patient. However, many of these tools have not
been validated in diabetic individuals. In this article we
will review the reproducibility and predictive value of the
followingsurrogatemarkersofatherosclerosis:intima–media
thickness (IMT), arterial stiffness and flow-mediated dilation
(FMD). We will discuss the diagnostic accuracy and pre-
dictive value of imaging techniques used for direct anatomic
assessment of coronary atherosclerosis (coronary artery
calcium [CAC] scores and multi-slice computed tomography
[MSCT] angiography) and functional tests that detect
myocardial ischaemia (ambulatory ECG, exercise ECG,
stress echocardiography (SE) and nuclear myocardial perfu-
sion imaging (MPI) by single photon emission computed
tomography (SPECT). Finally, the value of these non-
invasive techniques as endpoints in clinical trials and as risk
estimators in diabetic patients will be discussed. We will
concentrate on methods of risk stratification and the imple-
mentation of non-invasive techniques in patients with type 2
diabetes, as the value of these techniques has scarcely been
studied in type 1 diabetes.
Surrogate markers of atherosclerosis
Carotid IMT
Since its introduction in the early 1990s, IMT, especially
carotid IMT (CIMT), has increasingly been used as a
surrogate marker of atherosclerotic disease. IMT can be
assessed non-invasively using B-mode ultrasound. Two
approaches are used: (1) multiple measurements of CIMT
in the near and far walls of the three main segments of the
carotid arteries (common carotid, bifurcation and internal
carotid); and (2) automated computerised measurement of
CIMT, restricted to the far wall of the distal common carotid
artery. Computerised measurement of CIMT is superior in
terms of precision and reproducibility, with an approximately
3% difference between two successive measurements [3].
As a result, common CIMT has become a valid tool for
large-scale multicentre studies. However, the common
carotid artery is less likely to have intrusive plaque than
the bifurcation and internal segments of the carotid arteries.
CIMTcorrelates withprevalent CVD and withrisk factors
for CVD [4]. In prospective studies, CIMT has proven to be
a consistent and independent predictor for coronary events
and stroke in the general population [5–6].
CIMT in type 2 diabetes Mean common CIMT in middle-
aged individuals is reported to range from 0.71–0.98 mm in
diabetic patients vs 0.66–0.85 mm in controls [7–9]. In
diabetic individuals without a history of myocardial infarc-
tion CIMT is similar to that in non-diabetic individuals with
ahistoryofmyocardialinfarction[9]. Progression of maximal
CIMT in the Insulin Resistance Atherosclerosis Study was
twice as high in persons with diabetes vs controls [10], but
other studies report lower rates [11]. In type 2 diabetes,
prevalent CVD is associated with higher CIMT [9]. In two
prospective studies, baseline CIMT was shown to be an
independent predictor of cardiovascular events [12–13].
However, when Folsom and colleagues analysed CIMT in
a large cohort that included 1500 diabetic participants, they
found that CIMT has predictive value for future coronary
events only in combination with several other novel risk
factors [14].
CIMT measurements show good reproducibility. CIMT
is increased in type 2 diabetic patients with CVD and is
an independent predictor of coronary events. However,
the magnitude of its predictive value when added to
other risk factors is questionable
Arterial stiffness
Whereas IMTis a marker of structural vessel wall properties,
arterial stiffness reflects functional wall properties. Stiffness
can be measured in many ways, including distensibility,
pulse wave velocity (PWV) and augmentation index (AIx).
Distensibility, defined as the change in arterial lumen
diameter during the cardiac cycle, can be evaluated by ultra-
soundimagingusingwall-trackingsystemsbasedonDoppler
shift or using B- or M-mode. The change in arterial diameter
1582 Diabetologia (2008) 51:1581–1593duringthecardiaccyclevariesbyabout5–6%inmiddle-aged
individuals [15]. PWV is the speed with which the arterial
pressure wave progresses through the arterial tree, and this
increases with increasing vascular stiffness. The PWV can
be determined either by placing a probe on two sites and
recording the waveform simultaneously, or by recording the
waveforms independently and comparing the time delay at
both sites with a simultaneously measured QRS complex.
PWV gradually increases with age, from about 4 m/s in the
third decade to 10 m/s in the ninth decade. The AIx, which
is the augmentation of aortal pressure as a percentage of
pulse pressure, has also emerged as a parameter for arterial
stiffness (Fig. 1)[ 16–17]. Studies report excellent repro-
ducibility of PWV, with a CVof approximately 3.2%, which
is lower than that for distensibility indices (CV 5.3%) or
AIx (CV 10.1%) [17–19].
In cross-sectional studies, arterial stiffness is strongly
associated with age and classical risk factors for CVD [15,
20–21], andithasbeenreportedtoberelated toangiographic
coronary atherosclerosis [17]. In a cohort of men aged
>70 years, baseline arterial distensibility predicted cardio-
vascular mortality during a 2 year follow-up, but added
little to clinical risk estimation [22]. However, in a Danish
populationstudy,aorticPWVpredictedacompositeofcardio-
vascular events outcome above and beyond traditional risk
factors [23].
Arterial stiffness in type 2 diabetes Diabetic patients have
increased arterial stiffness [17, 24]. Compromised carotid
distensibility and PWV have been demonstrated even before
the onset of diabetes, in patients with impaired glucose
tolerance. Healthy offspring of type 2 diabetic patients have
a higher PWV than matched controls [17, 25]. Arterial
stiffness in diabetes is related to prevalent CVD [16] and
has shown to be an independent predictor of CHD [26].
Baseline distensibility did not predict mortality in 140
individuals with impaired glucose tolerance during a follow-
up period of 6.6 years [18]. Conversely, PWV does seem to
have a reasonable predictive value for mortality in patients
with impaired glucose tolerance and type 2 diabetes [24].
The reproducibility of PWV is superior to that of AIx
and distensibility. Therefore, PWV is the most accepted
method for estimating vascular stiffness. Vascular
stiffness is increased in type 2 diabetic patients with
CVD and has been shown to predict cardiovascular
mortality
FMD
FMD of the brachial artery is a non-invasive technique for
measuring endothelial function. FMD is measured with
B-mode ultrasound or a wall-track system. The brachial
artery is visualised in the elbow, and by inflating a cuff
(mostly distal to the elbow) for 4 min, hypoxia is created.
After deflation, reactive hyperaemia induces shear stress,
therebystimulating NO synthesis, resulting in NO-dependent
dilation [27]. FMD is thus defined as the percentage change
in the diameter of the brachial artery after hypoxia,
estimated to be 5–10% in healthy individuals. The observed
brachial artery dilatation has shown to be closely related to
coronary vasoreactivity [28].
FMD fluctuates during the day and is influenced by the
temperature, stress, diet, glucose levels and the menstrual
cycle [29]. Within-subject variability of FMD is therefore
often poor, with CVs ranging from 14–50% [29–30]. In
spite of the biological variation, there is good intra- and
interobserver reproducibility for measurements of baseline
Fig. 1 The pulse pressure wave form. a The incident wave generated
by the left ventricle (in the ascending aorta). b Waves reflected back
from the peripheral vascular bed (ascending aorta). c The resultant
wave in the ascending aorta, which is a combination of (a) and (b).
AIx is the measure of additional pressure to which the left ventricle is
subjected asaresultofwavereflection andiscalculatedas:AIx=(a/[b+
a])×100
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artery (diameter variations of approximately 4%) [30].
FMD ranges from about 10% in young adults to 0% in
patients with established coronary heart disease (CHD), and
it has proven to be predictive for the presence of CHD [31]
and for future coronary events in high-risk populations
[32]. High sensitivity and high negative predictive values
were calculated using cut-off points of 8.1–10% [32]. FMD
has not been independently associated with coronary events
in patients at lower risk [33].
FMD in type 2 diabetes Type 2 diabetes is associated with
endothelial dysfunction. The underlying mechanisms are sus-
pected to be related to hyperglycaemia (sorbitol, hexosamine,
protein kinase C, and AGE pathways) and insulin resistance,
which results in mitochondrial superoxide overproduction,
and thus decreased NO availability [34–35]. Clustering
of risk factors such as dyslipidaemia, hypertension and
obesity in the metabolic syndrome play an additional role.
Insulin-mediated vasodilatation is at least in part NO-
dependent, thus explaining how insulin resistance may cause
endothelial dysfunction.
The predictive value of endothelial dysfunction in epi-
cardial coronary arteries of diabetic patients has been
established for long-term coronary events [36]. However, to
our knowledge, no studies to date have evaluated the
relationship between FMD and prediction of coronary events
in diabetes.
FMD is a marker of endothelial function. It should only
be assessed under strictly constant external and physical
circumstances, so that reproducibility is optimised. The
potential of FMD for the identification of type 2
diabetic patients at risk for CVD is as yet unknown
Direct anatomic assessment of coronary atherosclerosis
CAC scores
Anatomical and intravascular studies have illustrated that
the presence of coronary calcium is indicative of coronary
atherosclerosis [37]. Coronary calcification can be detected
non-invasively by electron beam CT (EBCT), and more
recently by MSCT. Agatston et al. developed a coronary
calcium scoring algorithm, based on calcification volume
and density, that is now widely used in clinical practice
[38]. The extent of coronary calcium increases with age,
and is, on average, higher in men than in women [39–40].
CAC scores in type 2 diabetes Diabetic patients without
manifest CVD have a higher CAC score than non-diabetic
individuals, independent of classical risk factors [41–43]. In
addition, CAC scores show significantly more progression
over time in patients with diabetes than in non-diabetic
patients [44].
In a study by Raggi et al. [45], 10,377 patients (903 with
diabetes) were followed for a period of 5.0±3.5 years after
CAC imaging. Mortality increased with increasing baseline
CAC levels for both diabetic and non-diabetic individuals.
However, despite similar CAC scores, there was a greater
increase in mortality in diabetic than non-diabetic patients
for every increase in CAC score [45]. The predictive value
of CAC scores in diabetes has been questioned by Qu et al.
[46], whofoundnosignificantrelationshipbetweencoronary
events and CAC scores during a 6 year follow-up of 269
diabetic patients [46].
CAC score is associated with prevalent CVD in diabetes.
However, CAC scores may underestimate the risk for
CVD in type 2 diabetic patients
MSCT coronary angiography
The application of MSCT scanners for non-invasive coronary
angiography has developed rapidly over recent years.
Employment of 16 and 64 slice systems have demonstrated
a sensitivity ranging from 83–99% and a specificity of
between 93% and 98% [47–51]. Several studies have
demonstrated that CT angiography has a high negative
predictive value of 99% on average [47–51]. Therefore, the
technique is currently most suited to exclude CHD.
Besides visualisation of the coronary artery lumen (Fig. 2),
CT angiography allows the identification of non-stenotic
atherosclerosis and the various types of plaques. In addition,
chronic myocardial infarction and left ventricular ejection
fraction can be assessed. Non-stenotic atherosclerosis may
prove to be a predictor of coronary events; however, this
remains to be determined in prospective long-term clinical
studies. Plaques can be classified as non-calcified, mixed or
calcified. Initial comparisons have shown that calcification
may represent the duration of atherosclerosis, whereas non-
calcified and mixed lesions are more frequently observed in
patients with an acute coronary syndrome [52].
MSCT is subject to a number of limitations, including
exposure to a relatively high dose of radiation, currently in
the range of 9–12 mSv [47, 51], lower accuracy in the
presence of severe calcification and movement artefacts,
and limited application possibilities in case of irregular
1584 Diabetologia (2008) 51:1581–1593heart rate [49–51]. Taking the radiation exposure and the
high negative predictive value of MSCT angiography into
consideration, this technique is recommended for excluding
CHD in patients of intermediate risk.
MSCT coronary angiography in type 2 diabetes MSCT
angiography has demonstrated a higher percentage of non-
calcified and calcified plaques and a relatively lower per-
centage of mixed plaques in diabetes [53], which can be
explained by the rapid progression of atherosclerosis. Schuijf
et al. have reported a sensitivity and specificity of 95% for
detection of stenosis. Inclusion of uninterpretable segments
reduced sensitivity and specificity to 81% and 82%, respec-
tively [54]. In an evaluation of the diagnostic accuracy of
16 slice MSCT angiography, there were no statistically sig-
nificant differences between the diabetic and non-diabetic
individualsinthestudypopulation[55]. Importantly, negative
predictive value of MSCT angiography in diabetes was
found to be 98% and 100% on segmental and patient basis,
respectively [55].
The prevalence of CHD has been assessed by MSCT
angiographyin70asymptomaticpatientswithtype2diabetes.
The majority of the patients (80%) had atherosclerosis
(obstructive CHD [luminal narrowing ≥50%] in 26%, non-
obstructiveCHDin54%ofpatients)[56]. Thus, results on the
use of non-invasive MSCT angiography for CHD screening
and as a prognostic indicator in the diabetic population
appear promising, but further studies in larger population
groups are needed.
MSCT angiography has good sensitivity, specificity and
negative predictive value for identification of CHD in
diabetic patients. However, assessment of CHD by
MSCT in asymptomatic type 2 diabetic patients should
be limited to patients at high risk, because of exposure
to high radiation and contrast as well as cost factors
Functional tests in assessment of coronary artery
disease
Functional tests detect myocardial ischaemia which is the
physiologic consequence of coronary obstruction. These
include: ambulatory ECG, exercise ECG, stress echocardiog-
raphy and nuclear myocardial perfusion imaging.
Ambulatory ECG
It has been postulated that periods of silent myocardial
ischaemia (SMI), which can be detected with ambulatory
ECG, precede a first coronary event. Ambulatory ECG
monitoring can be performed with a three-channel recording
system for a continuous period of 48 h. Transient myocardial
ischaemia is defined as the presence of episodes showing
>0.1 mV horizontal or downsloping ST-segment depression.
The sensitivity of ambulatory ECG for detecting CHD is
poor, ranging from 19–62% [57–59]. Compared with
coronary angiography, the specificity of ambulatory ECG
ranged between 54% and 92% [57–60]. Frequent episodes
of transient ischaemia detected by ambulatory ECG have
shown to be a marker for an increased coronary event rate
in asymptomatic middle-aged men and in patients with
known CHD [61].
Ambulatory ECG in type 2 diabetes The prevalence of SMI
in diabetes as assessed by ambulatory ECG varies between
35% and 58% [62–64]. Although the prevalence of SMI
determinedbythismethodisexpectedtobehigherindiabetic
than non-diabetic individuals, findings have been inconsis-
tent. Comparison of diabetic and non-diabetic patients in the
Asymptomatic Cardiac Ischemia Pilot (ACIP) study, illus-
trated lower rates of asymptomatic ischaemia in diabetes,
despite more extensive and diffuse coronary disease in the
non-diabetic group [65]. A study comparing exercise ECG
with ambulatory ECG for detection of SMI in diabetes
reported that ambulatory ECG identified ischaemia only in
diabetic patients with three-vessel disease, whereas exercise
Fig. 2 An asymptomatic patient with type 2 diabetes was screened
for CAD using MSCT angiography. a The occluded right coronary
artery (RCA) is easily visible using the three-dimensional volume
rendering technique, which provides an overview of coronary
anatomy. Arrows indicate occlusion. b Multiplanar reconstruction of
the RCA gives a more precise overview of abnormalities. c, d
Multiplanar reconstruction of the left anterior descending (LAD) and
left circumflex (LCx) coronary arteries
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[66]. In one study, patients with previously detected silent
ischaemia had a higher incidence of new coronary events
(87%) than those with no silent ischaemia (51%) during a
40 month follow-up period [63]. Further studies are needed
to validate the prognostic value of SMI detected by
ambulatory ECG.
The diagnostic value of ambulatory ECG for CHD is  
poor. The predictive value of ischaemia detected by
ambulatory ECG in type 2 diabetic patients has not been 
extensively studied
Exercise ECG
The exercise ECG is considered positive for myocardial
ischaemia if horizontal downsloping or upsloping ST-
segment depression of ≥0.1 mV occurs at least 0.08 s after
the J point. In a pooled meta-analysis of 24,074 patients who
had undergone both an exercise ECG and conventional
coronary angiography, mean sensitivity and specificity were
calculated to be 68% and 77%, respectively, for the diagnosis
of CHD by exercise ECG [67]. Sensitivity was higher in
three-vesseldisease[67]. In addition to myocardial ischaemia,
the exercise ECG provides information on exercise capacity
and haemodynamic response, which both have prognostic
value [68].
The prognostic significance of exercise-induced myocar-
dial ischaemia has been evaluated in prospective studies
[69–70]. In a population-based study, an average follow-up
period of 10 years was completed in 1,769 asymptomatic
men who had undergone an exercise ECG [69]. The risks
of acute coronary events and cardiac death were increased
1.7- and 3.5-fold, respectively, in men with SMI compared
with men without SMI, after adjusting for conventional
factors.
Exercise ECG in type 2 diabetes mellitus The use of an
exercise ECG for diagnosing myocardial ischaemia specif-
ically in the setting of diabetes has not been assessed in
large studies. In an evaluation of the correlation between
the ECG exercise test and coronary angiography for the
identification of significant coronary artery stenosis in 59
diabetic patients, the sensitivity and specificity were 75%
and 77%, respectively [71]. The mean positive predictive
value of the exercise ECG for predicting angiographic
coronary disease varies between 70% and 90% [72–73].
However, the test is often inconclusive or unfeasible in
diabetic patients (approximately 32%) because exercise
capability may be impaired by peripheral vascular or
neuropathic disease [72]. Furthermore, the specificity of this
method is lower for detecting significant coronary artery
disease in diabetes because of the presence of microvascular
disease.
Abnormal ECG stress tests have shown to be indepen-
dent predictors of coronary events [74–75]. A 38 month
follow-up of 262 asymptomatic diabetic patients who had
undergoneamaximalECGstresstestshowedagoodnegative
predictive value (97%) for major cardiac endpoints [74].
Gerson et al. [75] showed that the exercise ECG successfully
identified all diabetic patients who developed clinical CHD
within 50 months, but provided little prognostic information
after the first 50 months, suggesting the need for serial
testing.
Exercise ECG has moderate sensitivity and specificity
for detection of CHD. During intermediate follow-up
exercise ECG has been shown to have a good predictive
value for coronary events. Application of exercise ECG
as a screening tool in type 2 diabetes is limited as the
test is often inconclusive
SE
SE is a well-established functional technique for assessing
CHD that can be used to demonstrate inducible wall motion
abnormalities in the general population. Exercise or a
pharmacological form of stress can be used. In the case
for the former, echocardiography is performed shortly after
exercise. This method provides additional information on
exercise capacity, symptoms and haemodynamic response,
which are beneficial prognostic factors. A potential hin-
drance may be the rapid resolution of ischaemia after
exercise, and therefore normalisation of any wall motion
abnormality prior to echocardiography. Pharmacologically
induced stress echocardiography is preferred in those with a
limited exercise capacity. An additional advantage is that
images are obtained during stress. In a meta-analysis of
10,817 patients in which dobutamine was compared with
stress testing with adenosine or dipyridamole, dobutamine
echocardiography had the highest combination of sensi-
tivity (80%) and specificity (84%) for the diagnosis of
coronary disease [76]. The accuracy of the method is
dependent on the degree of stenosis, the amount of
myocardium at risk and the degree of induced wall motion
abnormality [77]. False-negative results are more likely
with submaximal exercise (in the case of exercise-induced
stress), single-vessel disease and moderate stenosis (50–
70%) [78].
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ischaemic segments predict the likelihood of coronary
events during long-term follow-up among members of the
general population with known or suspected CHD [79–80].
However, in a 10 year follow-up of 1,832 asymptomatic
patients who underwent SE, exercise testing and a resting
echocardiogram, SE did not offer additional prognostic
information in terms of identifying patients at a higher risk
of coronary events [81].
SE in type 2 diabetes The diagnostic accuracy of SE for
significant CHD in diabetes has been verified in two studies.
In one study in which 55 diabetic patients underwent
dobutamine SE and invasive angiography, the sensitivity
and specificity of SE were 81% and 85%, respectively [82].
Another study that compared SE with coronary angiogra-
phy in diabetic patients (n=52) reported a similar sensitiv-
ity (82%) but a much lower specificity (54%) [83].
In a prospective study, SE plus an exercise ECG were
used to screen 71 diabetic patients with unknown asymp-
tomatic cardiac disease and two or more cardiovascular risk
factors [84]. Those who obtained an abnormal result in one
test underwent coronary angiography, and if necessary,
revascularisation. Compared with patients randomised to
the control arm (n=70), coronary events were significantly
reduced in the screening arm during follow-up [84]. The
preclinical diagnosis of CHD by SE may therefore be
effective. However, more studies are needed to determine
the prognostic role of SE in screening for cardiac disease in
asymptomatic diabetic patients.
The sensitivity and specificity of SE for diagnosing
extensive CHD are satisfactory. However, the predictive
value of a positive test in type 2 diabetes needs to be
further analysed
Nuclear SPECT MPI
The majority of studies on ischaemia have used SPECT
MPI. This imaging modality reveals the presence and extent
of perfusion defects. Images are taken following exposure
to stress (exercise of pharmacological) and at rest, allowing
the identification of fixed and reversible defects (Fig. 3).
The dimensions of the left ventricle and ejection fraction
can also be determined. An analysis of the diagnostic
accuracy of pharmacologically induced stress MPI in a
pooled meta-analysis of 10,817 patients with angiographic
data reported a mean sensitivity and specificity of 88% and
77%, respectively [85].
Perfusion defects are significant predictors of coro-
nary events in patients with known or suspected CHD
[86]. However, over a follow-up period of 4.6 years the
presence of perfusion defects did not independently predict
coronary events in a purely asymptomatic group of
volunteers [87]. Normal MPI results have shown a low
coronary event rate (1%) over a 5 year follow-up period
[88]. Significant predictors of future coronary events after
pharmacologically induced stress MPI include large
defects, defects in multiple coronary artery territory
suggestive of multi-vessel disease, major irreversible
defects, left ventricular dilatation and decreased resting left
ventricular ejection fraction [86].
Nuclear SPECT MPI in type 2 diabetes To our knowledge,
the diagnostic accuracy of MPI in diabetes has only been
studied by Kang et al. [89], who performed MPI and
conventional coronary angiography n 138 diabetic patients.
Mean sensitivity and specificity were 86% and 56%, respec-
tively, for ≥50% coronary stenosis, and 90% and 50% for
≥70% coronary stenosis [89].
In asymptomatic diabetic patients, the rate of SMI
diagnosed by stress MPI ranges from 17–59% (Table 1)
[90–95]. In general, a higher percentage of perfusion defects
has been detected in retrospective studies [90–91]. In the
Detection of Ischemia in Asymptomatic Diabetics (DIAD)
study, which included 1,123 participants, the occurrence of
perfusion defects was not significantly associated with the
traditional risk factors for CVD [92].
Fig. 3 Myocardial perfusion imaging was carried out in the patient
described in Fig. 2, in whom coronary abnormalities had been
observed on MSCT angiography. a A perfusion defect was observed
in the posterolateral segment (indicated by the arrows) during stress,
which did not exist during rest (b), indicating ischaemia. c Partial
ischaemia was observed during stress, shown by an increase in the
size of the defect in the inferior segment (indicated by the arrow)
compared with the rest scan (d)
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reversible perfusion defects have been shown to be
predictors of coronary events in asymptomatic diabetic
patients [93–95]. Rajagopalan et al. [90], categorised
diabetic patients, according to SPECT imaging scans, as
being at high, intermediate or low risk. The annual
mortality rate was 5.9%, 5.0% and 3.6%, respectively, with
a significant difference in mortality (p<0.001) between the
three groups [90]. The long-term prognostic value of MPI
in asymptomatic diabetic patients needs to be further
analysed. It is speculated that concurrent abnormalities of
perfusion imaging scans in diabetic patients with normal
coronary angiograms may be caused by microangiopathy or
endothelial dysfunction, and therefore represent an in-
creased likelihood of future coronary events [96].
Conclusion
CIMT, arterial stiffness and perhaps FMD are abnormal long
before the onset of diabetes. Therefore these measurements
are the most likely to be useful for the identification of at risk
patients during the early stages of atherosclerotic disease,
when functional wall properties are still reversible. However,
further studies are necessary to evaluate whether these tools
provide any additional prognostic value when used in
combination with clinical risk scores (Table 2)b e f o r et h e y
can be implemented on large scale in clinical practice.
In individuals with a strong clinical suspicion of
advanced CHD, cardiac imaging techniques are more
warranted. When functional techniques are compared,
ambulatory ECG and exercise ECG are less sensitive and
specific than functional cardiac imaging tests for the
detection of ischaemia in type 2 diabetes. Head-to-head
comparison has revealed that SPECT MPI has a higher
sensitivity than SE for the detection of multi-vessel and
single-vessel CHD [97]. Furthermore, the predictive value
of SPECT MPI in the diabetic population has been studied
more extensively than that of SE (Table 2). CAC scoring
and the more recently developed MSCT non-invasive
Table 1 Comparison of studies which have used single-photon emission-computed tomography myocardial perfusion imaging to detect silent
ischaemia in diabetic patients
Study group No. of
patients
Patient characteristics Study
nature
Abnormal results (%) Other details
Rajagopalan et al. [90] 1,427 No known cardiac history R 58% abnormal scans High-risk scans were associated
with ECG Q waves, PAD, HbA1c,
male sex, age, LDL-cholesterol
Patients with abnormal
resting ECG included
18% high-risk scans
(high risk: SSS ≤47)
Miller et al. [91] 1,738 No known cardiac history R 59% abnormal scans High-risk scans in 19.7%
Patients with abnormal
resting ECG included
Wackers et al. [92]
(DIAD study)
522 No known cardiac history P 22% abnormal results
(out of which, 73%
abnormal scans and
37% other
abnormalities)
Abnormal test result was not
associated with traditional cardiac
risk factors; 50% of patients were
incapable of exercise
Patients with abnormal
resting ECG excluded
Sultan et al. [93] 419 No known cardiac history P 17% abnormal scans
(abnormal: defect in
≥3/20 segments)
Male sex, triacylglycerol, low
creatinine clearance, HbA1c>8%
were independent predictors of
abnormal scans
Besides DM, ≥1
traditional cardiac risk factor
Patients with abnormal
resting ECG included
Zellweger et al. [94] 826 No known cardiac history P 39% abnormal scans
(abnormal: SSS <4
or SDS ≥2)
Valensi et al. [95] 370 No known cardiac history P 26% abnormal scans Silent ischaemia was associated
with higher age and triacylglycerol
and lower HDL levels
Besides DM, ≥2
traditional cardiac risk factors
Patients with abnormal
resting ECG excluded
DM, diabetes; P, prospective; PAD, peripheral arterial disease; R, retrospective; SDS, summed difference score; SSS, summed stress score
MPI shows good sensitivity but poor specificity (possibly
because of microvascular disease) for diagnosing CHD
in diabetes. Intermediate follow-up has shown a good
predictive value of MPI for coronary events in type 2
diabetes
1588 Diabetologia (2008) 51:1581–1593coronary angiography allow quantification of atheroscle-
rotic burden. CAC scores have been shown to predict
coronary events [56]. MSCT coronary angiography has
good sensitivity for the identification of prevalent CHD and
can therefore enable more widespread screening in combi-
nation with CAC scores in diabetes, but its use is limited by
radiation exposure and costs.
We propose an algorithm for the screening of asymp-
tomatic diabetic patients (Fig. 4). A selection strategy using
a CAC score >100 AU has been shown to be an effective
way of identifying patients with moderate to large perfusion
defects [98]. Nevertheless, recent observations have shown
that low CAC scores do not exclude CHD in diabetes [56].
Based on this, the initial step of our algorithm involves the
combined use of CAC assessment and exercise ECG to
maximise sensitivity for the detection of CHD. MPI or
MSCT coronary angiography seem to be justified for
individuals with a CAC score >100 or a positive exercise
ECG. Conventional coronary angiography can then be
considered in the presence of ischaemia according to stress
MPI or obstructive atherosclerosis illustrated by MSCT
angiography. Prospective studies may be conducted to
evaluate the effectiveness of such a screening approach.
The criteria for the selection of those asymptomatic
patients with type 2 diabetes who should undergo non-
invasive cardiac screening for risk stratification remain
controversial. The ‘two or more risk factors’ criterion for
screening, as suggested by the 1998 American Diabetes
Association guidelines, failed to accurately identify a large
number of patients with ischaemia in the DIAD study [92].
Future studies may prove non-invasive vascular tools such
as measurement of CIMT, PWV and FMD to be more
effective for the identification of patients at risk who should
be screened for CHD (Fig. 4).
Table 2 Comparison of various non-invasive vascular tools and cardiac imaging techniques
Tool/technique Reproducibility Detection of prevalent CAD Prediction of CAD events Details
Non-DM2 DM2 Non-DM2 DM2
1. Vascular tools
IMT Good:
variability <5%
++ [4]+ [ 9]+ + [ 5, 6]+ [ 12–14]
Vascular stiffness Mediocre:
variability 11–15%
++ [17]+ [ 16, 26]+ [ 22, 23]+ [ 18, 24]
FMD Poor:
variability up to 50%
++ [31] Unknown ± [32, 33] Unknown High intersession
variability
2. Anatomical tests
CAC scores Good ++ [37]+ + [ 56]+ + [ 100]± [ 45, 46]
Limited
studies
MSCT angiography Good ++ [47–51]+ + [ 54–56] Unknown Unknown High radiation doses
3. Functional tests
Ambulatory ECG Unknown ± [57–60]
Reasonable
sensitivity
±[ 65, 66]
Low sensitivity
+[ 61]± [ 63]
Limited
studies
Low specificity
Exercise ECG Unknown + [67]
Reasonable
sensitivity
+[ 71–73]
Reasonable
sensitivity
+[ 69, 70]+ [ 74, 75] Not feasible in 32% of
patients with DM2
Reasonable
specificity
Low specificity
Nuclear MPI Good + [85]
Good sensitivity
+[ 89]
Good sensitivity
++ [86–88]+ + [ 90, 93–
95]
Based on
intermediate
follow-up
More long-term
follow-up studies
in DM2 are needed Reasonable
specificity
Low specificity
SE Good + [76–78]
Good sensitivity
+[ 82, 83]
Limited studies
±[ 79–81]± [ 84]
Limited
studies
Relatively high false-
negative rate in
single-vessel disease
and moderate
stenosis
Good specificity Good sensitivity
Good specificity
++, strong and consistent association in several studies in multivariate analysis; +, association in most studies in multivariate analysis; ±,
association in some studies or association only in univariate analysis DM2, type 2 diabetes
Diabetologia (2008) 51:1581–1593 1589The future
In type 2 diabetic patients, plaque development is not only
accelerated but also distinct, exhibiting more lipid-rich
atheroma, macrophage infiltration and a higher thrombo-
genic potential compared with development in non-diabetic
individuals [99]. This implies that screening tools such as
magnetic resonance angiography, which enable assessment
of plaque composition and may reflect the real culprit, i.e.
plaque vulnerability, could emerge as more potent risk
predictors in diabetes. However, the application of magnet-
ic resonance angiography as a screening tool is not feasible
in the near future because of the high costs and complex
methodology involved.
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